Paul Lips

Paul Lips

Auto-generated profile, based on publicly available information

Paul Lips

Department of Endocrinology, VU University Medical Center, Amsterdam, Netherlands

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 1999 in Osteoporosis International
Verified
Journal Article
Closed access
PDF file
PLP. Lips
P. Lips
CCC. Cooper
C. Cooper
DAD. Agnusdei
D. Agnusdei
FCF. Caulin
F. Caulin
PEP. Egger
P. Egger
FOFor The Working Party For Quality Of Life Of The European Foundation For Osteoporosis
For The Working Party For Quality Of Life Of The European Foundation For Osteoporosis

1 March 2001 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
PLPaul Lips
Paul Lips
TDTu Duong
Tu Duong
AOAnna Oleksik
Anna Oleksik
DBDennis Black
Dennis Black
SCSteven Cummings
Steven Cummings
TNThomas Nickelsen
Thomas Nickelsen
Vitamin D deficiency leads to secondary hyperparathyroidism, increased bone turnover, and bone loss and, when severe, to osteomalacia. Vitamin D deficiency is common in elderly people, especially the institutionalized. The definition of vitamin D deficiency is hampered by the fact that large interlaboratory differences exist in assays for serum 25-hydroxyvitamin D (25OHD), the main circulating metabolite. The international Multiple Outcomes of Raloxifene Evaluation study, a large prospective intervention trial in postmenopausal women with osteoporosis, offered the opportunity to compare vitamin D status and parathyroid function throughout many countries over the world. For this study, baseline data were available from 7564 postmenopausal women from 25 countries on 5 continents. All women had osteoporosis, i.e. bone mineral density (BMD) at femoral neck or lumbar spine was lower than t-score −2.5, or they had 2 vertebral fractures. Serum 25OHD was measured by RIA, and serum PTH was measured by immunoradiometric assay. BMD was measured by dual x-ray absorptiometry. The mean (±sd) serum 25OHD was 70.8± 30.9 nmol/L. A low serum 25OHD (<25 nmol/L) was observed in 4.1% of all women in the Multiple Outcomes of Raloxifene Evaluation study, ranging from 0% in south east Asia (very few patients) to 8.3% in southern Europe. Serum 25OHD was between 25–50 nmol/L in 24.3% of the women. Serum 25OHD showed a significant seasonal relationship, with lower values in all regions in winter. Serum PTH correlated negatively with serum 25OHD (r = −0.25; P < 0.001). This significant negative correlation was observed in all regions. When serum 25OHD was less than 25, 25–50, or more than 50 nmol/L, respectively, mean serum PTH levels were 4.8, 4.1, and 3.5 pmol/L, respectively (by ANOVA, P < 0.001). Similarly, mean alkaline phosphatase levels were 83.7, 79.1, and 75.7 U/L (P < 0.001), respectively, with increasing serum 25OHD. The effect of serum 25OHD on BMD was only significant for the BMD of the trochanter where a serum 25OHD level less than 25 nmol/L was associated with a 4% lower BMD. After 6 months of treatment with vitamin D3 (400–600 IU/day) and calcium (500 mg/day), serum 25OHD increased from 70.8 ± 29.8 to 92.3 ± 28.6 nmol/L. Serum PTH decreased significantly after 6 months of treatment, and this decrease depended on baseline serum 25OHD. When baseline serum 25OHD was less than 25, 25–50, or more than 50 nmol/L, respectively, serum PTH decreased by 0.8, 0.5, or 0.2 pmol/L, respectively (P < 0.001). In conclusion, serum 25OHD was less than 25 nmol/L in 4% of the women, and this was associated with a 30% higher serum PTH. In 24% of the women serum 25OHD was between 25–50 nmol/L, associated with a 15% higher level of serum PTH compared with women with a serum 25OHD greater than 50 nmol/L. A low serum 25OHD level was also associated with higher serum alkaline phosphatase and lower BMD of the trochanter. Treatment with vitamin D3 and calcium increased serum 25OHD and decreased serum PTH significantly; the effect was greater for lower baseline serum 25OHD.

1 June 1996 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PKP van Kesteren
P van Kesteren
PLP Lips
P Lips
WDW Deville
W Deville
CPC Popp-Snijders
C Popp-Snijders
HAH Asscheman
H Asscheman
LGL Gooren
L Gooren
The effects of treatment with estrogens and antiandrogens in male to female (M-->F) transsexuals and androgens in female to male (F-->M) transsexuals on their respective bone metabolism, bone mineral density (BMD), serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 (IGFBP-3) levels were investigated. BMD and variables of bone turnover in serum were measured at baseline and after 3 months (except for BMD) and 1 yr of treatment in 56 M-->F and 35 F-->M transsexuals. Serum IGF-I, IGFBP-3, and propeptide of type I procollagen (P1CP) were measured at baseline and after 1 yr of treatment in 10 M-->F and 10 F-->M transsexuals. In M-->F, BMD increased significantly. Bone turnover decreased, as shown by a significant decline in levels of osteocalcin, alkaline phosphatase, P1CP, and fasting urinary calcium/creatinine and hydroxyproline/creatinine ratios. Serum IGF-I levels decreased significantly without significant changes in IGFBP-3 levels. In F-->M, BMD did not change. Bone formation increased, as suggested by an increase in alkaline phosphatase and a borderline increase in P1CP values. IGF-I levels increased significantly, whereas no significant changes were seen in IGFBP-3 levels. We conclude that in males, estrogens (in combination with antiandrogens) decrease bone turnover, with a subsequent increase in BMD and a decrease in serum IGF-I. In females, testosterone administration increases bone formation, but this is not reflected in an increased BMD, whereas serum IGF-I increases.

22 May 1999 in BMJ
Verified
Journal Article
Closed access
PDF file
PLPaul Lips
Paul Lips
Corticosteroid induced osteoporosis has presented a challenge to clinicians for many years. Bone loss during corticosteroid treatment is mediated by inhibition of gonadal and adrenal steroid production, leading to hypogonadism and a direct negative effect on calcium absorption and osteoblast function.1 Epidemiological data suggest that corticosteroid treatment doubles the risk of fractures of the hip and distal radius and at least quadruples the risk of vertebral fracture. How can this damage be limited? Corticosteroids are widely used, especially for rheumatoid arthritis, polymyalgia rheumatica, and chronic obstructive pulmonary disease. A cross sectional study in Nottinghamshire in over 65 000 patients showed that 0.5% were taking oral corticosteroids.2 Most were aged 60-80 years and the mean dose was 8 mg/day, with a median duration of treatment of three years. Only 14% of these patients had received preventive treatment for osteoporosis. If these data are extrapolated to the whole population, over 250 000 people in the United Kingdom are taking oral corticosteroids. Monitoring bone loss has become easy now that bone mineral density can be measured with dual energy x ray absorptiometry. Nevertheless, many patients taking long term corticosteroids are not referred for bone mineral density …

22 September 2000 in The Netherlands Journal of Medicine
Verified
Journal Article
Closed access
PLP Lips
P Lips
ECE.F.I Comans
E.F.I Comans
OHO.S Hoekstra
O.S Hoekstra
ECE van der Poest Clement
E van der Poest Clement
JMJ.C van Mourik
J.C van Mourik
GTG.J.J Teule
G.J.J Teule

1 May 2011 in Bone
Verified
Journal Article
Closed access
PDF file
KEK. Estrada
K. Estrada
EEE. Evangelou
E. Evangelou
YHY.-H. Hsu
Y.-H. Hsu
USU. Styrkarsdottir
U. Styrkarsdottir
CLC.-T. Liu
C.-T. Liu
FRF. Rivadeneira
F. Rivadeneira